Advertisement

PFO Device Closure

  • Lisa Bergersen
  • Susan Foerster
  • Audrey C. Marshall
  • Jeffery Meadows

Abstract

Device closure of PFO remains a relatively controversial topic in those with otherwise normal hearts. In this patient population.

Keywords

Antiplatelet Therapy Device Closure Tunnel Length Residual Shunt Transient Ischemic Attack 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Reference

Reference

  1. 1.
    Hung J, Landzberg MJ, Jenkins KJ et al. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol. 2000;35:1311–1316.PubMedCrossRefGoogle Scholar

Review Article

  1. Inglessis I, Landzberg MJ. Interventional catheterization in adult congenital heart disease. Circulation 2007;115:1622-1633PubMedCrossRefGoogle Scholar
  2. Mullen MJ, Hildick-Smith D, De Giovanni JV et al. BioSTAR Evaluation STudy (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation. 2006;114:1962-1967.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Lisa Bergersen
    • 1
  • Susan Foerster
    • 2
  • Audrey C. Marshall
    • 1
  • Jeffery Meadows
    • 3
  1. 1.Department of CardiologyChildren’s Hospital BostonBostonUSA
  2. 2.Washington University in St. LouisSt. LouisUSA
  3. 3.Division of Pediatric CardiologyUniversity of California at San FranciscoSan FranciscoUSA

Personalised recommendations